Background: Proton pump inhibitors are substituted benzimidazoles compounds, they are used as agents for the treatment of acid-peptic diseases. These compounds are metabolized by several enzymes, the genetic variations in these enzymes were thought to influence the pharmacogenetics of the proton pump inhibitors and in turn influence the outcome of the patients. Aim: To highlight the pharmaco-genetics of proton pump inhibitors Methods: Scientific websites were used to search for articles such as Pubmed and Google Scholar. Several keywords were used to obtain all possible articles concerned with the subject. Results: We reviewed 6 articles about the current subject, there were few articles about the pharmacology of proton pump inhibitors. Conclusion: Few studies have focused on the pharmacogenetics of proton pump inhibitors and most of them were trials, also there were no previous review articles studied this subject.
INTRODUCTION
Proton pump inhibitors (PPIs) are agents that considered as a major advance in the treatment of acid-peptic diseases. They are the most common class of medication prescribed in the primary care setting
[1]. These agents ranked in the top of 10 national health-related drug expenditures in US in 2015 [2] . The introduction of first PPI which was omeprazole (Prilosec), was in 1989, after that several PPIs became available [1] including rabeprazole, pantoprazole and lansoprazole [3] . PPIs are selectively and irreversibly inhibit the gastric hydrogen potassium adenosine triphosphatase (H+K+-ATPase) pump mechanism in gastric parietal cells [3, 4] . PPIs are used for the treatment of Barrett's esophagus, Zollinger-Ellison Syndrome, gastroesophageal reflux disease and peptic ulcer disease [3] . The pharmacological effects of most drugs are dependent on both the pharmacokinetic process and pharmacodynamics [5] . These processes in turn occur at variable levels in each individual, and the major determinant of this variability is genetics [5] . In the present review we highlighted the pharmacogenetics of PPIs as well as uses of PPIs.
MATERIALS AND METHODS
In the current review, we used the internet to get the articles related to our subject, we used several key words including PPI, PPI metabolism, Pharmacogenetics of PPI, PPI uses. Scientific web sites were used for researching for articles such as Pubmed, Google Scholar and research Gate. We obtained 17 articles, 11 of them were excluded as they didn't involve the main points we searched for, while 6 articles were reviewed. These 6 articles were published between 2002-2017. The study was done after approval of ethical board of King Fahad Central Hospital.
1.Pharmacology of Proton Pump Inhibitors (PPI):
PPIs are substituted benzimidazoles compounds which are administrated either as capsules or entericcoated tablets which pass through the stomach reaching to proximal small bowel where they are absorbed
[1]. After absorption, PPIs have short plasma half-life which ranges from one to 2 hours, while duration of action is much longer as they have a unique mechanism of action
As PPIs are lipophilic weak bases, they cross the parietal cell membrane and then enter the acidic parietal cell canaliculus. PPIs becomes protonated in the acidic environment, this results in producing the activated sulphenamide form of the drug which has the ability to bind covalently with the H+/K+ ATPase enzyme, this in turn results in irreversible inhibition of acid secretion by the proton pump Rabeprazole (Aciphex) differs from other PPI, where it forms a partially reversible bond with the proton pump, it is also activated at a broader range of gastric pH, so it has more effect on acidsuppressing than the other PPIs For resuming acid secretion, the parietal cell must activate resting pumps or produce new proton pumps There are 2 common approaches about the initiation of GERD treatment, but no one was approved to be superior, so the physician determines the most appropriate one Step-up therapy and Step-down therapy are the 2 approaches; the former begins with standard-dosage or over-the-counter H2 blockers and titrates to symptom control, while the later starts with once-or twice-daily PPI therapy and the dosage is changed or decreased to the lowest form of acid suppression which will control the patient's symptoms The most common variants and targets of pharmacogenetic tests are the single nucleotide polymorphisms (SNPs), which refers to change in a single base in the nucleotide sequence
[5]. It was suggested that CYP2C19 genetic polymorphism can result in a significant phenotypic variation in the activity of this isoenzyme, hence the metabolism and efficacy of the PPIs change either
[27]. There were 21 variants of CYP2C19 assigned from *1 to *20. The wild type allele is CYP2C19*1, while CYP2C19*2 is a variant allele which contains 681G>A on exon 5 that causes a splicing defect, it is the main genetic defect responsible for the polymorphism of Smephenytoin metabolism in humans
[5]. CYP2C19*3 carries the 636G>A SNP, this leads to a premature stop codon in exon 4. Both CYP2C19*2 and *3 are null alleles, which cause absence of enzymatic activity
[32]. These two alleles are responsible for the majority of PMs of CYP2C19
[33]. In a systemic review Another study [38] showed that variations in CYP2C19 genotype affected the eradication rates of lansoprazole-based therapy. GERD is refractory to PPI therapy in 10% of patients and the most important reason for that is differences in the efficiency of the metabolism of the drug [5]. It was also referred that the genotype is also crucial for the nocturnal acid bouts, which are influential factors in the treatment outcome. These intrusions are more frequent in rapid metabolizers, this resulted in a suggestion for patients who were refractory to standard doses of PPI to receive an increased dose Pharmaco-genetics also influences the safety profile of PPIs in case of GERD where it requires long treatment periods Risk of hyperplasia of enterochromaffin-like cells, which is related to the development of carcinoid tumors has been reported 
CONCLUSION
Proton pump inhibitors are agents that are effective in treating peptic ulcers regardless their causes as they are effective antacids. The pharmacogenetics of these agents are influenced by the genetic variations of the enzyme that metabolize them, so the outcome of patients may differ as a result of the genetic variations. There are scarcity studies that were conducted on the proton inhibitors pharmacogenetics and most of them were trials and showed unclear results. It is recommended to establish studies which focus on the pharmacogenetics of proton pump inhibitors which could help in the prediction of the outcome of patients . 
